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Abstract 
Aims 
Systematically reviewing the literature found Orthostatic Hypotension (OH) to be associated 
with an increased risk of incident dementia but limited data were available in those at highest 
risk, the hypertensive oldest-old. Our aim was to analyse the relationship between OH and 
incident cognitive decline or dementia in this group and to synthesize the evidence base 
overall. 
Method and results   
Participants aged≥ 80 years, with hypertension, were from the Hypertension in the Very 
Elderly Trial (HYVET) cohort. OH was defined as a fall of >=15mmHg in systolic and or 
>=7mmHg in diastolic pressure after two minutes standing from a sitting position. 
Subclinical orthostatic fall with symptoms (SOH) was defined as a fall<OH but with 
unsteadiness, light-headedness or faintness in the week before blood pressure measurement. 
Proportional hazard regression was used to examine the relationship between baseline OH, 
SOH and cognitive outcomes. There were 3121 in the analytical sample, 538 with OH. OH 
was associated with increased risk of cognitive decline (906 events) Hazard Ratio(HR)1.36 
(95%Confidence Interval 1.14:1.59). For incident dementia (241 events) HR1.34(0.98:1.84).  
When competing risk of cardiovascular events were taken into account results were 
HR1.39(1.19:1.62)  and HR1.34 (1.05:1.73) respectively. SOH was associated with an 
increased risk of cognitive decline HR1.56(1.12:2.17) and dementia HR1.79(1.00:3.20). 
Combining the results from the HYVET cohort in a meta-analysis with the existing published 
literature in this area found a 21%(9%:35%) increased risk of dementia with OH. 
Conclusion 
OH indicates an increased risk of dementia and cognitive decline. SOH may also be 
considered a risk factor, at least in older hypertensive adults. Questions remain regarding the 
mechanisms and whether interventions to reduce impact of OH could protect cognition.  
 
Keywords  
Dementia   Cognitive decline 
Orthostatic hypotension  Hypertension 
Older adult   
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1. Introduction  
Orthostatic hypotension (OH) is a relatively common autonomic failing and is often 
associated with functional impairment (1). It is commonly defined as a fall in systolic Blood 
Pressure (BP) of at least 20mmHg and /or a fall of at least 10 mmHg in diastolic BP within 3 
minutes of standing,  
Older adults are at increased risk of OH due to impaired compensatory mechanisms including 
decreased baroreceptor (pressure) sensitivity, increased arterial stiffness and reduced 
parasympathetic tone (2,3).  OH is likely to be a risk factor for a variety of negative health 
consequences, including cardiovascular events, falls, mortality and poor cognition. This is 
particularly relevant in older adults where hypertension is prevalent and where levels of 
frailty and comorbidity may also be high (1-3).  In 2014 a systematic review found OH to be 
associated with an increased risk of cardiovascular events (4). The evidence for an 
association between OH and cognitive decline in the same systematic review was equivocal. 
The review found only two eligible studies; one reported no relationship between OH and 
cognitive outcomes (5) and one other reported an increased risk of cognitive decline with OH 
(6). There remains a lack of high quality evidence, and remaining uncertainty, relating to the 
association between OH and cognitive decline or dementia.  
A link between OH and increased risk of cognitive decline is plausible, either directly via 
variable cerebral perfusion or via increased cardiovascular risk, clinical or subclinical 
ischaemic events, or, via failing homeostatic mechanisms associated with both OH and 
cognitive decline (7). This is also particularly relevant to older adults and those with 
hypertension in whom cerebral auto-regulatory mechanisms may be less able to adapt (1).   
With an ageing population and an increased risk of cardiovascular, and cognitive, outcomes 
associated with increasing age alongside recent work on the role of OH  (1-4,7) it is timely  to 
evaluate OH as a predictor for cognitive decline and dementia. To give an updated and 
unbiased background overview of the current evidence we used systematic methods to review 
the literature relating to OH as a risk factor for incident cognitive decline and dementia. See 
supplementary figure 1 and text file 1 for details. Briefly, 21 longitudinal studies on the 
relationship between orthostatic hypotension and incident cognitive decline or incident 
dementia were found (5,6,9-27) including populations from Sweden (22 23),  Italy(24),  the 
Netherlands (25), Singapore (6) , the United States (26) and France (27). See supplementary 
tables 1, 2. Study sample mean age ranged from mid (23,26)  to late-life (6,24,25,27,33) and 
follow-up from ~1-28 years (6,23- 27,33).  
Three studies reported presence of OH was associated with an increased risk of dementia (22, 
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25, 27). One study found no relationship between baseline OH and dementia (23), one found 
no relationship between OH and cognitive decline (26). Two found no association between 
OH and risk of a fall in cognitive screening score (6,24). Study quality was adequate although 
details were often lacking, see supplemental table 3.   
Overall, evidence suggests that a diagnosis of OH may be associated with a subsequent 
increased risk of dementia. However, there are no data available on those at highest risk of 
hypertension, OH and cognitive decline or dementia (the oldest old). Furthermore, few 
studies have investigated the relationship between the magnitude of the orthostatic fall and 
the degree of risk (i.e. the potential dose response), or the possible influence of ‘sub-clinical’ 
orthostatic fall. A greater understanding of relationship between orthostatic fall and cognitive 
outcome in older adults is essential to be able to identify those at risk of cognitive decline or 
dementia and to provide appropriate clinical support. 
Our aim was to examine the relationship between orthostatic fall and subsequent cognitive 
decline or dementia in an older adult hypertensive population using data collected as part of 
the Hypertension in the Very Elderly Trial and to combine our results with the existing 
evidence base using meta-analysis.  
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2. Methods  
HYVET was a double blind placebo controlled trial of an antihypertensive regimen (thiazide-
like diuretic, indapamide 1.5 sustained release, with the optional addition of an angiotensin 
converting enzyme inhibitor, perindopril 2-4mg) in those aged 80 and over. Participants with 
hypertension were recruited from over 90 primary and secondary care centres in 13 countries 
and randomised to receive trial treatment or matching placebo. All required ethical approvals 
were obtained. Participants were seen during a two-month placebo run-in phase, at baseline, 
every three months during the first year and every six months thereafter. Cognitive function 
was assessed at baseline and annually thereafter using the Mini-Mental State Exam (MMSE). 
A reduction in MMSE score to below 24 or by more than three points in twelve months was 
classified as cognitive decline and triggered a dementia assessment. Dementia was diagnosed 
in accordance with the Diagnostic Statistical Manual IV (DSMIV). Dementia was classified 
as present or absent. An independent expert dementia committee blind to trial treatment 
allocation had access to all data and reviewed and validated all dementia endpoints.  Other 
trial endpoints were reported as they occurred and included death, stroke, myocardial 
infarction and incident or worsening heart failure. Validation of trial endpoints was carried 
out by a trial endpoint committee of international experts blinded to trial treatment allocation 
and with full access to supporting documentation, for example, death certificates, 
hospitalisation reports etc:   
To collect data on self-reported symptom burden HYVET trial participants were also asked to 
self-complete a symptom questionnaire at baseline and annually thereafter. This 
questionnaire was based on the Bulpitt and Fletcher questionnaire and included a list of 
symptoms relevant to hypertension and its treatment (28). Participants were asked to rate the 
level to which they had been affected by a symptom over the last week. The symptoms light-
headedness, unsteadiness and faintness were selected as relevant to orthostatic drop.  
The full details of the HYVET protocol have been published elsewhere (29,30). In brief, to 
enter the HYVET trial participants were required to be aged 80 or over at randomisation, to 
have no clinical diagnosis of dementia, a mean systolic BP 160 to 199mm Hg and a standing 
systolic BP ≥140mm Hg. The sitting BP was taken twice after sitting for five minutes and the 
standing BP taken twice after standing for two minutes. At study baseline BP was measured 
using a mercury sphygmomanometer.  As supine BP was unavailable OH was calculated 
based on a fall of >=15mmHg systolic BP and or a fall of >=7mmHg diastolic BP from 
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sitting to standing  (31, 32).  A novel category of subclinical orthostatic fall with recent 
symptoms (SOH) was also created. SOH was defined as any fall in systolic BP of <15mmHg 
on standing and any fall in diastolic BP of <7mmHg on standing plus symptoms of light-
headedness and or unsteadiness and or faintness reported by the participant as having 
bothered them ‘a lot’ or ‘extremely’ during the preceding week. The SOH category was 
adapted from the orthostatic intolerance definition used by Elmståhl et al (22) and intended to 
examine a potential subclinical population (3).   
 
2.1. Statistical Methods 
The analytical data set consisted of HYVET trial participants who had at least one repeated 
assessment of cognitive function (allowing evaluation of cognitive decline), complete 
baseline BP measurements and, in accordance with the literature (6,22,25) were without prior 
stroke. OH was classified as present or absent at baseline.  
The difference in baseline characteristics between those who were included in the analytical 
sample and those who were excluded, and between those with and without OH, was assessed 
using Chi squared and Wilcoxon tests, as appropriate. Proportional hazard (Cox) regression 
was used to assess the relationship between those classified as having OH and subsequent 
cognitive decline or incident dementia. Time to event was calculated from trial entry (the date 
of first cognitive and blood pressure measure) to the earliest date of event, date of death or 
date of last follow up. The date of the study visit where cognitive decline was identified was 
taken as the date of event for cognitive decline. The date that cognitive decline was identified 
was also used for date of dementia where further testing confirmed dementia diagnosis. This 
is a pragmatic choice since the time interval between the visit where cognitive decline was 
identified and the subsequent examination to verify diagnosis of dementia varied and as the 
onset of dementia is an insidious process. Models were stratified (by age (80-84, >=85), sex 
and education) and adjusted for key cardiovascular and cognitive risk factors (baseline sitting 
systolic and diastolic BP, trial treatment (antihypertensive or placebo) and presence of 
diabetes). Proportional hazard assumptions were checked using Grambsch and Therneau tests 
(33). Overall model fit was assessed visually by plotting the Nelson-Aalen cumulative hazard 
function against the Cox-Snell residuals. Analyses carried out using SAS 9.3, Stata and 
Statsdirect 3.  
The incidence of mortality, cardiovascular events (myocardial infarction, stroke or heart 
failure), cognitive decline and/or dementia may be interrelated or may all be considered 
manifestations of the same cardiovascular disease process. We therefore performed two 
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further Cox regression analyses, each using a composite endpoint  combining cognitive and 
cardiovascular events in a time to first event model to give greater statistical power and a 
more holistic outcome measure. In the first, incident dementia or fatal and non-fatal 
cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event 
and in the second, incident cognitive decline and fatal and non-fatal cardiovascular events 
(heart failure, myocardial infarction, stroke) were defined as an event.  
Additional analyses were performed with adjustment for incident OH occurring during study 
follow-up; and, because blood pressure variability may increase the risk of both OH and 
cognitive decline, analyses were rerun with additional adjustment for visit to visit variability 
calculated as the standard deviation of the sitting systolic BP values. 
 
Further analyses in the subset of participants who also had symptom data (i.e. had completed 
the symptom questionnaire) allowed comparison of those with OH, SOH and neither. The 
baseline characteristics of these three groups were compared using chi squared and analysis 
of variance tests for categorical and continuous variables, as appropriate. Pairwise differences 
were investigated post-hoc using the Tukey-Kramer (equal variances) or W test (unequal 
variances) for continuous variables and by inspection of the adjusted chi-squared residuals for 
categorical variables.  
Proportional hazards (Cox) regression was used to assess the relationship between orthostatic 
status and subsequent cognitive decline or incident dementia with orthostatic status 
categorised as a 3-level variable (OH, SOH or neither (reference group)).  There were no 
missing data for the exposure, outcome or confounding variables used in the analyses.  
 
2.2. Sensitivity analyses 
The Cox regression analysis was repeated: (i) in those with baseline MMSE >26 (those 
scoring above 26 at baseline are considered unlikely to have pre-existing cognitive decline, 
the selection of this population therefore allowed us to rerun the analyses with less risk of 
including undiagnosed dementia cases.); (ii) for systolic and diastolic OH separately; (iii) for 
continuous BP fall and risk of subsequent cognitive decline or incident dementia; (iv) using 
the traditional and more severe classification of OH (a fall of >20mmHg systolic and or 
>10mmHg diastolic);  
 
Finally the association between baseline OH and subsequent attrition (mortality or drop out) 
was examined in the analytical sample and inverse probability weighting used to evaluate 
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potential bias stemming from including only those with data on cognitive decline and without 
stroke.   
 
2.3. Meta-analysis  
Where possible the results from the HYVET analyses were combined with the existing 
evidence base was combined with using meta-analytical techniques. 
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3. Results  
3.1. Study population  
There were 3845 participants randomised into the HYVET trial with a mean follow up of 2.0 
years. Of those, 508 were excluded from the analysis because they had no cognitive follow-
up assessment and a further 216 due to prior stroke.  The analytical sample therefore included 
3121 with data on OH and outcome. The subset of those with symptom data and in whom 
SOH could be calculated contained 2109 participants. (See supplementary Figure 2 for 
details). 
 
3.2. Orthostatic hypotension (OH) 
3.2.1. Characteristics of the sample (OH) 
There were 538 participants with OH and 2583 without. Those with OH had higher sitting 
systolic BP (P<0.0001) and lower standing systolic (P<0.0001) and diastolic pressure 
(P<0.0001) as would be expected. There were also older (P=0.004), They also had a lower 
mean MMSE score at baseline (P=0.0003), shorter follow-up (P<0.0001) and a higher 
percentage of this group were classified as having incident cognitive decline (P<0.0001) (see 
Table 1 for details). 
Table 1 here  
3.2.2. Proportional hazard regression (OH) 
The estimates of the hazard ratios from the Cox regression models for the association 
between baseline OH and risk of cognitive decline (Hazard Ratio (HR) 1.36 (1.15:1.59)), and 
between baseline OH and development of dementia (HR1.34 (0.98:1.84)), were similar. 
(Table 2). There was little change in the estimates of hazard ratios when composite endpoints 
combining cognitive and cardiovascular outcomes were used, HR1.39 (1.19:1.62) for 
cognitive decline and cardiovascular events, and HR1.34 (1.05:1.72) for dementia and 
cardiovascular events. There was no relationship between OH and mortality or cardiovascular 
events alone. Further adjustment for blood pressure variability did not change the direction, 
magnitude or significance of the results. 
There were 315 incident OH cases occurring during study follow-up n=169 (5.6/100 patient 
years of follow-up) in the placebo and n=146 (4.5/100 patient years) in the actively treated 
group. Additional adjustment for incident OH resulted in the relationship between OH and 
incident dementia reaching statistical significance.  
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Further sensitivity analyses rerunning fully adjusted models in those with baseline MMSE 
scores >26 (n=1648) resulted in a similar pattern of results and statistical significance as seen 
when analysing the whole cohort. The only difference was a loss of statistical significance for 
one analysis, the relationship between OH alone and cognitive decline.  
Table 2 here 
 
3.3. Subclinical orthostatic fall with recent symptoms (SOH) and orthostatic hypotension 
(OH) 
3.3.1. Characteristics of the sample (SOH, OH) 
In the subset of those for whom symptom data were available (n=2109) 105 reported SOH, 
381 OH and 1623 neither. The baseline characteristics of the three groups are summarised in 
Supplementary Table 4.  
When examining the participants with both cognitive and symptom data there were 105 with 
subclinical orthostatic fall and positive symptoms, seven with symptoms but neither 
subclinical nor clinical orthostatic fall and four with symptoms and clinical fall. There are 
significant differences in the majority of measures between these groups at baseline (all 
except sitting systolic BP) but there is no consistent suggestion of a linear trend and the only 
clinically significant differences were between those without any orthostatic fall and those 
with OH.  
3.3.2. Proportional hazard regression (SOH, OH) 
The estimates of HRs from the Cox regression models are shown with the associated 95% 
confidence intervals in Table 3 and Figure 1.  Both SOH and OH were associated with an 
increased risk of cognitive decline. For SOH, HR1.56 (95%CI 1.12:2.17) and for OH HR1.40 
(95%CI 1.15:1.69). For cognitive decline and cardiovascular events the results were SOH, 
HR1.51 (95% CI 1.11:2.06) and OH, HR1.43 (95% CI 1.20:1.72), respectively).  SOH was 
also associated with an increased risk of dementia HR1.79 (95% CI 1.00:3.20) and dementia 
and cardiovascular events HR1.79 (95%CI 1.15:2.78).  
Further adjustment for blood pressure variability did not change the direction, magnitude or 
significance of the results. Additional adjustment for incident OH resulted in the relationship 
between OH and the composite endpoint, incident dementia with cardiovascular, events 
reaching statistical significance.  
Further sensitivity analyses rerunning fully adjusted models in those with baseline MMSE 
scores >26 and symptom data (n=914) resulted in a similar pattern of results but the 
association between OH and cognitive decline was no longer significant.  
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Additional analyses examining cardiovascular events and mortality alone found SOH to be 
associated with an increased risk of cardiovascular events HR2.28 (95% CI  1.25:4.14) and 
mortality HR2.97 (95% CI 1.76:5.01).  
Figure 1 here. Table 3 here 
 
Further examination of the role of symptoms (from the symptoms questionnaire) revealed 
that presence of self-reported light-headedness and or unsteadiness and or faintness alone 
(regardless of orthostatic fall) and experienced over the preceding week were not associated 
with incident cognitive decline or dementia. Rerunning the analysis without the inclusion of 
symptom data (i.e. SOH classified based on subclinical orthostatic fall alone) resulted in non-
significant relationships between sub-clinical orthostatic fall and cognitive decline HR1.01 
(0.82:1.24) and dementia HR 1.05(0.70:1.58).  
 
Model fit was adequate in all cases and the proportional hazards assumption was not violated. 
 
3.4. Sensitivity analyses 
3.4.1. Systolic hypotension and diastolic hypotension.  
The analyses were repeated with OH defined using systolic blood pressure fall, systolic OH 
(n=218) or diastolic blood pressure fall, diastolic OH (n=400) (Supplementary table 5). 
Diastolic OH was associated with an increased relative risk of; cognitive decline HR1.47 
(1.23:1.75), dementia HR1.69 (1.22:2.34), cognitive decline and cardiovascular events 
HR1.49 (1.26:1.75) and dementia and cardiovascular events HR1.54 (1.18:2.00).There were 
no significant associations for systolic OH.  
Repeating the analyses selecting only those with systolic OH but without diastolic OH 
(n=138) and diastolic OH without systolic OH (n=320) did not materially change the results.  
3.4.2. Orthostatic fall  
We investigated the relationship between magnitude of the orthostatic fall at baseline and risk 
of cognitive decline by repeating the Cox regression analysis with orthostatic fall as a 
continuous variable and for systolic and diastolic BP separately. On average there was a 26% 
increased relative risk of cognitive decline per 10mmHg increase (i.e. greater fall in BP) in 
orthostatic drop in diastolic BP HR1.26 (1.09:1.42). For systolic BP the results were HR1.04 
(0.94:1.15) per 10mmHg increase.  
3.4.3. Traditional and more severe classification of OH (a fall of >20mmHg systolic 
and or >10mmHg diastolic);  
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The Cox regression analysis was repeated using the classic, more conservative, definition of 
OH (see methods section) and the results presented in Supplementary Table 6. Orthostatic 
hypotension was associated with an estimated 49% increased relative risk of developing 
cognitive decline HR=1.49 (95%CI 1.16 to 1.90). This did not change markedly when 
cognitive decline and cardiovascular events were combined. 
3.4.4. Attrition and inverse probability weighting:  
There was no association between OH and subsequent drop out or death (events=650) 
OR0.86 (95% CI 0.67 to 1.10). Inverse probability weighting weighted by age, sex and 
baseline MMSE score found similarly positive associations between OH and incident 
cognitive decline (β0.078 (95%CI 0.045:0.130)) P<0.0001 and dementia (β0.027 
(0.003:0.052)) P=0.034. This implies that the exclusion of those with prior stroke and without 
follow-up cognitive assessment did not bias the sample in such way as to materially affect the 
results.  
 
3.5. Meta-analysis combining the results from the systematic review and HYVET study.  
Summary data showing the relationship between presence or absence of OH and incident 
dementia was reported in the published literature for the Rotterdam Study (HR1.15 (95%CI 
1.00:1.34)), the 3 City Study (HR 1.19 (95%CI0.98:1.46)), the Malmö study (HR 1.18 
(0.73:1.89)), the Swedish Good Aging in Skåne Study (OR 1.93 (95%CI1.19:3.14)), and the 
HYVET study (HR 1.34 (95%CI 0.98:1.84)) (22,23,25,27).  
The meta-analysis suggested that increased relative risk of dementia was associated with 
presence of OH. The pooled ratio was 1.21 (1.09:1.35) for fixed effects analysis. See 
supplementary analyses 1 for details of the meta-analysis and forest plot showing the five 
included studies. The I2 value for the meta-analysis was 10.4% and there was no significant 
risk of publication bias (Egger bias p=0.1463). There were insufficient data available from 
the previously published studies to allow separate meta-analysis relating to systolic, diastolic 
or subclinical OH.  
See supplementary tables 1-2 for details of the studies included in the meta-analysis 
(populations, age, sex, follow-up, assessment of OH, assessment of cognitive function, 
analysis methods and results for these studies). Supplementary table 3 further details the 
assessment of study quality and risk of bias.   
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4. Discussion  
These analyses present new data and shed new light on the relationship between OH and 
cognitive impairment and dementia.  
 
4.1. Orthostatic hypotension and HYVET 
When the relationship between OH and incident cognitive decline and dementia was assessed 
in an older adult hypertensive population from the HYVET trial, baseline OH (sitting to 
standing) was associated with a 36% increased risk of cognitive decline HR1.36 (1.15:1.59) 
and a similar point estimate but non-significant relationship with incident dementia HR1.34 
(0.98:1.84). Using composite endpoints (i.e. including cardiovascular events) resulted in 
significant associations with both cognitive decline and dementia, and did not change the 
magnitude of the point estimates. Further examination of the relationship between subclinical 
orthostatic drop and cognitive outcomes revealed SOH to be associated with a 56% increased 
risk of cognitive decline HR1.56(1.12:2.17)) and a 79% increased risk of incident dementia 
HR1.79 (1.00:3.20)). Results were similar for composite cognitive-cardiovascular endpoints. 
When systolic and diastolic OH were examined separately results were significant only for 
diastolic drop.  
The relationships between OH and cognitive outcomes in the HYVET trial are not entirely 
congruent with the literature. In the HYVET data the relationship between OH and cognitive 
decline was stronger than the equivalent relationship with dementia although both were of 
similar magnitude, however, there were fewer dementia cases than cases of cognitive decline 
and thus less power to detect a relationship. The strength of the relationship with SOH and 
cognitive decline was also greater than the relationship between SOH and incident dementia, 
however both were statistically significant despite the restricted numbers available for these 
analyses.  Neither presence of symptoms alone, nor subclinical orthostatic fall without 
symptoms were associated with an increased risk of cognitive decline or dementia therefore 
the presence of symptoms alongside orthostatic drop may be of particular importance in 
identifying those at risk of cognitive decline or dementia. Unfortunately there were too few 
cases of OH and presence of symptoms to allow evaluation of this category.  
 
The stronger relationship between diastolic as compared to systolic OH and cognitive 
outcomes in the HYVET trial must be interpreted with caution. Although it is similar to that 
reported for the Swedish Malmo study and may represent a particular risk associated with a 
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more pulsatile flow and decrease of perfusion in diastole, another explanation relevant to the 
HYVET data is that the trial inclusion criteria are based on systolic rather than diastolic 
pressures meaning that the systolic pressures were more homogeneous and clustered just 
above the required cut-point for trial entry. To enter the HYVET trial participants were 
required to have a mean systolic BP 160 to 199mmHg and a standing systolic BP 
≥140mmHg. This resulted in a study population without severe OH and, since there were 
fewer entrants with very high systolic BP, a mean baseline systolic BP close to the entry 
threshold. Diastolic pressures did not suffer from the same limitation.   
Further limitations include the potential for unmeasured confounding and use of a clinical 
trial population with randomly allocated antihypertensive treatment and placebo arms. 
Although we found no relationship between trial treatment group and cognitive outcomes 
(34) and the analyses were adjusted for trial treatment group it remains possible that there 
may have been an undetected impact of trial treatment on the relationship between orthostatic 
drop and cognitive outcomes. The relatively short follow up and the potential for interaction 
between blood pressure and cognitive function over a decades long prodromal period prior to 
the identification of decline is an additional limitation. We have a lack of understanding 
relating to the long term relationship between blood pressure and cognition over the life-
course and a lack of data prior to participant entry into the HYVET trial at ~80 years of age 
which inevitably restricts our ability to evaluate causality. There is also a challenge in 
disentangling the potential relationship between early cognitive decline, impaired medication 
adherence and subsequent change in BP control and OH. Despite this, the results from the 
HYVET population are in line with those of longer population studies (22,23,25,27). It may 
be that OH had been present and incrementally increasing risk either directly or indirectly for 
many years prior to study start, however, we have no data on OH prior to entry into the 
HYVET trial. Alternatively the association of OH and cognitive outcomes in this very elderly 
population may represent failing homeostatic mechanisms and increased blood pressure 
variability associated with both OH and cognitive decline. Additional adjustment for visit to 
visit variability had no impact on the results, however, a lack of sufficient data relating to 24 
hour blood pressure variability (112 HYVET participants had ambulatory blood pressure 
measurement at baseline) prevented further examination of this area. In fact, since studies 
with both long and short term follow up demonstrate a relationship between OH and 
increased risk, the exact causal pathways, whilst still needing to be established (35), do not 
change the overall categorization of OH as an easily measurable factor signalling increased 
risk.  
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4.2. Orthostatic hypotension and meta-analysis combining the published literature and the 
HYVET results 
The meta-analysis combining HYVET with the published literature found OH to be 
associated with a 21% increased risk of dementia. Inevitable limitations include variation in 
length of follow-up, confounders, population characteristics and in the definition and 
assessment of OH and cognitive outcome plus risk of bias present in the constituent studies. 
This means that generalisability is limited and, as is common in meta-analyses, caution must 
be applied.  
 
4.3. Summary 
The literature overall, including HYVET, is remarkably similar in showing a relationship 
between OH and risk of dementia. In addition a possible dose response may mean that even 
subclinical orthostatic fall is associated with raised risk especially in the presence of 
symptoms associated with OH. However, our analyses cannot establish causality and further 
research is needed to more fully understand the nature of the relationship between orthostatic 
drop, speed of recovery, potential difference between systolic and diastolic drop, role of 
symptoms, related measures such as blood pressure variability, arterial stiffness, impact of 
early cognitive change on medication availability or adherence and causal pathways (35, 36). 
Causality in this area is complex and although we know from the Discontinuation of 
Antihypertensive Treatment in Elderly People on Cognitive Functioning trial that stopping 
antihypertensives, at least in those with mild cognitive deficit, increased probability of 
recovery from OH, this association was not present in the intention to treat analysis, and had 
no impact on cognitive measures (37). Furthermore there was no relationship between 
antihypertensive use and OH in HYVET and antihypertensive use reduced risk of 
cardiovascular events and mortality (30) meaning we cannot simply recommend the cessation 
or reduction of antihypertensives.   A key question therefore is whether other interventions to 
minimise the impact of OH (35-38) have any impact of cognitive outcomes.  
 
Conclusion  
Orthostatic hypotension appears to be associated with an increased risk of dementia and of 
cognitive decline and may be a clinically useful indicator of increased risk. Attention should 
also be paid to those with subclinical orthostatic drops alongside symptoms indicative of 
variable cerebral perfusion.   
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Figure 1 Showing the Hazard Ratios and 95% Confidence Intervals for risk of cognitive 
decline and dementia for Orthostatic Hypotension (OH) and Subclinical Orthostatic 
Hypotension with symptoms (SOH) compared to neither.  
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Table 1 Characteristics of those with Orthostatic Hypotension (OH) compared to those 
without OH in the HYVET population 
 
 
   
Population characteristics  
mean (Standard Deviation) or  
n (%) 
With OH 
 
N=538 
Without OH 
 
N=2583 
P= 
Age 83.9 (3.3) 83.5 (3.1) P=0.004 
Female 61.5 (331) 61.5 (1588) P=0.984 
Sitting systolic BP 174.5 (9.8) 173.3 (9.2) P<0.0001 
Sitting diastolic BP 91.1 (8.7) 90.9 (9.0) P=0.688 
Standing systolic BP 162.0 (10.9) 169.3 (10.2) P<0.0001 
Standing diastolic BP 82.8 (9.1) 89.9 (8.9) P<0.0001 
Systolic orthostatic fall 13.4 (7.5) 4.0 (5.5) P<0.0001 
Diastolic orthostatic fall 8.3 (4.8) 1.0 (4.3) P<0.0001 
Diabetes 46 (8.6) 249 (9.6) P=0.4666 
Mini Mental State Exam (MMSE) 
score 
24.9 (3.7) 25.4 (3.8) P=0.0003 
Incident dementia  50 (9.3) 191 (7.4) P=0.133 
Incident cognitive decline 
(Protocol definition: MMSE fall) 
194 (36.1) 712 (27.6) P<0.0001 
Incident cardiovascular event 
(stroke, myocardial infarction, 
heart failure) 
37 (6.9) 157 (6.1) P=0.485 
Death 31 (5.8) 183 (7.1) P=0.269 
Follow up in years (baseline to last 
available data) 
2.2 (1.5) 2.4 (1.5) P<0.0001 
Number randomised to trial 
treatment placebo arm 
268 (49.8) 1273 (49.3) P=0.8497 
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Table 2 Hazard ratios (HR) and associated 95% confidence intervals (CI) for the effect of Orthostatic Hypotension on risk of cognitive 
decline, dementia and cardiovascular events.   
Stratified by age (80-84, >=85 years), sex and education. Adjusted for baseline sitting systolic and diastolic BP, trial treatment and presence of diabetes.  
 
 
Outcome Cognitive decline Dementia 
Cognitive decline and 
cardiovascular events** 
Dementia and cardiovascular 
events* 
Orthostatic 
Hypotension 
(OH) 
 
Number of 
participants 
(events) 
HR (95% CI) 
Number of 
participants 
(events) 
HR (95% CI) 
Number of 
participants 
(events) 
HR (95% CI) 
Number of 
participants 
(events) 
HR (95% CI) 
No 2,583 (712) 1.00 2392 (191) 1.00 1778 (805) 1.00 2256 (327) 1.00 
Yes 538 (194) 1.36 (1.15:1.59) 488 (50) 
1.34 
(0.98:1.84) 
322 (216) 1.39 (1.19:1.62) 457 (81) 
1.34 
(1.05:1.72) 
* incident dementia, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event  
**cognitive decline, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event.   
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Table 3 Hazard Ratios and 95% Confidence Intervals for effect of Subclinical orthostatic fall with recent symptoms and orthostatic 
hypotension on risk of adverse events (N=2100).  
Stratified by age (80-84, >=85 years), sex and education. Adjusted for baseline sitting systolic and diastolic BP, trial treatment and presence of diabetes. 
 
 
 
Cognitive decline Dementia 
Cognitive decline and 
cardiovascular events ** 
Dementia and 
cardiovascular events * 
Number 
of events  
Hazard Ratio 
(95% 
Confidence 
Intervals (CI) 
Number 
of events 
HR (95% CI) 
Number 
of events 
HR (95% CI) 
Number 
of events 
HR (95% 
CI) 
Neither 
641 
1.00 
180 
1.00 
720 
1.00 
293 
1.00 
SOH 1.56 (1.12:2.17) 
1.79 
(1.00:3.20) 
1.51 
(1.11:2.06) 
1.79 
(1.15:2.78) 
OH 1.40 (1.15:1.69) 
1.26 
(0.87:1.84) 
1.43 
(1.20:1.72) 
1.32 
(0.98:1.78) 
* incident dementia, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event  
**cognitive decline, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, stroke) were defined as an event.   
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Supplemental material 
Supplementary text 1 Systematic review   
 
Methods , search strategy and study selection 
The databases MEDLINE and MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations and 
Embase Classic+Embase were searched using search terms including orthostatic hypotension, dementia, multi-infarct 
dementia, vascular dementia, alzheimer*, or cognit* adapted for optimised searching with Medline and Embase. (See 
supplement for details). Understanding of the relationship between BP and cognition has developed extensively over the 
last 20 years and search results were limited to those from 1997 to July 2017, further limitations included human rather 
than animal studies and articles in English (no resources were available for translation). Conference abstracts, editorials, 
comment, letters and review articles were excluded.  The resulting abstracts were evaluated independently by two 
reviewers (RP and JP) and potentially eligible articles were selected for full text review.  Any discrepancies were 
resolved by discussion between the two reviewers. All full text articles were extracted using a standardised data 
extraction table. Data from the included studies relating to population source, percentage of the sample that were female, 
length of follow-up, assessment of orthostatic hypotension, cognitive outcomes, analysis methods and results were 
extracted. In order to ensure the most robust assessment of incident dementia or cognitive decline data relating to 
samples that were pre-specified as cognitively intact at baseline were preferentially extracted.   
For inclusion, articles were required to report on prospective longitudinal studies and on the relationship between 
orthostatic hypotension and incident cognitive decline (using cognitive measures collected at a minimum of two time 
points) or incident dementia.  To ensure a broad assessment of the literature there were no minimum requirements for 
length of follow up, definition of OH or of cognitive decline or dementia. Study quality was examined per study using 
key questions based on the Critical Appraisal Skills Programme (8).   
The systematic review is registered with the PROSPERO International prospective register of systematic reviews no. 
CRD42017075003 
 
 
Results 
Six hundred and twenty four abstracts were identified from database searching of Medline, 2805 from Embase and a 
further seven from reference searches. Abstract review resulted in 21 articles selected for full text evaluation of which 
seven were found to be eligible. Of the 14 that were excluded six were cross sectional (9-14), one was a case-control 
study (21), six lacked information on OH (15-20) one did not report results for incident cognitive decline  (5).  See 
supplemental figure 1, PRISMA flow chart. The seven eligible papers reported on longitudinal population studies from 
Sweden (22 23), (The Swedish Good Aging in Skåne Study (SGASS) and the Malmö Preventive Project), Italy (the 
Progetto Veneto Anziani study (PVA)), (24),  the Netherlands (25), (the Rotterdam study), Singapore (Chinese adults)  
(6) (the Singapore longitudinal Aging Studies Cohort (SLASC)), the United States  (USA) (the Atherosclerosis in the 
Community (ARIC) study) (26) and France (the 3-City study)(27). 
The Malmö study population had a mean age of 45 (Standard Deviation (SD) 7)) years at baseline (23). The ARIC study 
included those aged between 45-64 at baseline and reported mean ages of 53.9 without OH and 57.3 with OH (26). The 
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Rotterdam and Singapore studies recruited those aged 55 and older at baseline and had mean ages of 68.5 (SD 8.6) (25) 
and 65.5 (SD 7.4) (6) years respectively. The Swedish SGASS study selected from nine age cohorts ranging from 60 to 
93, mean age 68 (SD 8.5) at baseline (33). The Italian PVA study and the French 3-City study recruited those aged 65 
and over. The PVA study also over sampled older adults. Baseline mean age in the PVA study was 71.4 (5.2) (24) and in 
the 3-City study 73.4 (SD4.9) (27). Follow up varied widely from one-two years (6), 4.4 years (24), six years (22), 7.5 
years (27), ~6-9 years (26), 15.3 years (median) (25) and 28 years (SD 4) (23). The Swedish populations were 37% and 
54% female respectively (22, 23), in the ARIC study 44.9% were female in those without OH and 45.8% in those with 
OH (26), in the Italian study females made up 59.4%(24), the Netherlands study 59.7%  (25), the 3-City Study 60.5% 
(27) and in Singapore 65.8% (6).   
OH was defined with slight differences in all five studies (supplemental table 2). All studies calculated orthostatic fall 
from a supine to standing position, however, the Skåne Study used a BP fall of >20mmHg systolic BP (BP) or >10mmHg 
diastolic BP after standing for 1-10 minutes or a fall of >40mmHg systolic or >20 diastolic immediately after standing 
(22). The other five studies used a fall of >=20mmHg systolic or >=10mmHg diastolic but within three minutes of 
standing (25), after three minutes of standing (7), after one minute of standing (23) after either one or three minutes of 
standing (24) immediately after standing (27) or with BP taken every two seconds for two minutes after standing (26). 
The 3-City study also calculated mild OH as a fall of  >10mmHg systolic or >5 diastolic and severe OH as a fall of  
>30mmHg systolic or >15 diastolic  immediately after standing (27). The prevalence of OH was 19% in the SGASS 
study (22), 18.6% in the Netherlands (25) 18.3% in Italy (24) 16.6% in Singapore (6), 13% in the 3-City study (27)  5.1% 
in the USA and 2.1% in the Malmö study (23). The Rotterdam study further reported a prevalence of OH at 30.6% in 
those aged 75 and over (25), the 3-City study reported 32% as having mild OH and 4.5% severe OH (27) and the 
Swedish SGASS study classified Orthostatic Intolerance (OI) as those with a BP (BP) fall less than that required for OH 
but with the presence of relevant symptoms e.g. unsteadiness (22).  
Four studies used the Mini-Mental State Exam (MMSE) to assess cognitive function (6, 22, 24, 25). The ARIC study 
used a neuropsychological battery (26). The SGASS and 3-City studies used the Diagnostic Statistical Manual (DSM) IV  
and the Rotterdam study the DSMIIIR (22, 25, 27), for diagnosis of dementia, with additional standard criteria for 
dementia type (25,  27) and the Malmö study validated dementia diagnoses from a national registry using the DSMIIIR 
(23). See supplemental table 2.  
Principal summary measures were OR and HR. All studies except the ARIC study reported data from populations that 
were specified as cognitively intact at baseline. The Malmö, SGASS, the Rotterdam and the 3-City studies reported that 
the presence of OH was likely to be associated with an increased risk of dementia (22, 23, 25, 27). For the SGASS this 
was a 93% increased risk OR 1.93 (1.19:3.14) (22); for the Rotterdam study, HR1.15 (1.00:1.34) (25). The Malmö study 
found a HR of 1.18 (0.73:1.89) for incident dementia, a HR of 1.02 (0.89:1.15) per 10mmHg fall in systolic BP and HR 
1.22 (1.01:1.44) for diastolic BP  (23). The  3-City study reported a 26% increased risk of dementia, HR1.26 (1.03:1.53) 
using a competing risk model taking illness and death into account and a HR of 1.19 (0.98:1.46) using a Cox proportional 
hazard regression model (27). The 3-City study also found statistically significant increases in risk of dementia when 
using the definitions of both mild and severe OH for both competing risk and Cox regression models, see supplemental 
table 2 for details (27). The SGASS further reported that OI may increase risk, particularly when subjective memory loss 
was taken into account (22). The ARIC study found no relationship between baseline OH and the quintile showing 
greatest cognitive decline for each cognitive test (26). Similarly the SLASC found no association between OH and risk of 
a fall in MMSE score (OR0.87 (0.61:1.23) (6). The PVA study reported similar results OR 0.78 (0.69:1.05) for cognitive 
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decline (a drop of >=3 MMSE points over follow-up) and OR1.01 (0.90:1.15) for cognitive impairment (MMSE <=24) 
(24). There were no obvious relationships between length of follow up or study gender balance and outcome.  
Overall study quality was adequate although full study details were often lacking, see supplemental table 3 for details. 
Studies used relatively standard but varying assessments of BP and cognitive outcomes and due to attrition all reported 
results for potentially selective populations (6, 22, 24,25, 26, 27). In particular, the SLASC, the ARIC and two Swedish 
studies reported high attrition rates (6, 22, 23, 26) and for the SLASC study the follow up was too short to exclude 
reverse causality (6). There was insufficient information across the studies to allow meaningful comment on dementia 
type.  
Conclusion 
Overall, therefore, there is evidence to suggest that a diagnosis of OH may be associated with a subsequent increased risk 
of dementia and cognitive decline, however, there are no data available on the oldest old, that is those at highest risk of 
hypertension, OH and cognitive decline or dementia. Furthermore, few studies have investigated the relationship between 
the magnitude of the orthostatic fall and the degree of risk (i.e. the potential dose response), or the possible influence of 
‘sub-clinical’ orthostatic fall and symptoms potentially associated with orthostatic fall. A greater understanding of 
relationships between orthostatic fall and cognitive outcome in older adults is essential to be able to identify those at risk 
of cognitive decline or dementia and to provide appropriate clinical support. 
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Supplementary text 2 search strategy   
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily and Ovid MEDLINE(R) <1946 to Present>26 July 2017 
Search Strategy: 
--------------------------------------------------------------------------------  
1     hypotension.mp. or exp Hypotension, Orthostatic/ or exp Hypotension/  
2     exp Alzheimer Disease/ or alzheimer*.mp.  
3     exp Dementia/ or Dementia, Multi-Infarct/ or exp Frontotemporal Dementia/ or Dementia, Vascular/ or 
dementia.mp.  
4     exp Cognition Disorders/ or exp Cognition/ or cognit*.mp.  
5     2 or 3 or 4  
6    1 and 5  
7     limit 6 to (english language and humans and yr="1997 -Current")  
 
Database: Embase Classic+Embase <1947 to 2017 July 26 
Search Strategy: 
--------------------------------------------------------------------------------  
1     orthostatic hypotension.af.  
2     (dementia or multi-infarct dementia or vascular dementia or alzheimer* or cognit*).af.  
3     1 and 2  
4     limit 3 to (human and english language and yr="1997 -Current")  
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Supplemental figure 1   
 
  
Records from Medline 
searches 
(n =624) 
Records identified from 
Embase searches 
(n =2805) 
Records after duplicates removed 
(n =646) 
Records screened 
(n =646) 
Records excluded 
(n =602) 
Full-text articles assessed 
for eligibility 
(n =21) 
Full-text articles excluded, 
with reasons 
(n =14) 
6 Cross sectional studies  
1 Case control study 
6 Lacking information on 
orthostatic hypotension 
  
1 did not report incident 
cognitive impairment or 
dementia  
Studies included in 
qualitative synthesis 
(n =7) 
Additional records identified 
through other sources 
(n =8) 
Flow chart, systematic review. 
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Supplementary figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total HYVET sample n=3845 
Analytical sample for 
Subclinical orthostatic fall with 
recent symptoms (SOH) 
n=2109 
Excluded for prior stroke n=216 
Excluded for lack of cognitive follow up  n=508 
Participant did not complete symptom 
questionnaire n=1012 
Analytical sample for Orthostatic 
Hypotension (OH)  alone n=3121 
Flow chart, analytical sample. 
Meta-analysis: 
Combining results from the HYVET trial 
with those from the published literature 
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Supplemental table 1  Characteristics of the longitudinal study populations reporting on orthostatic hypotension and cognitive outcomes in those without prior cognitive impairment 
Study  Population Age (years) 
Percent 
female 
Follow up 
Swedish Good Aging in 
Skåne Study. Elmståhl et 
al 2014 
Longitudinal general population study.  
 
This sample excluded those with baseline Mini-Mental State Exam 
(MMSE) <24 or with a diagnosis of Mild cognitive Impairment 
(MCI) or dementia or prior stroke, myocardial infarction, angina 
pectoris and those unable to be tested for orthostatic hypotension. 
Baseline n=2931, 1832 were re-examined, 710 died or left the study, 
23 had missing data. The final analytic sample was 1480 
 
68 (Standard Deviation 
(SD) 8.5.  
 
From 9 age cohorts, aged 
60,66, 72, 78, 81, 84, 87, 
90, 93 
54% 
6 years  
 
(assessments at baseline and 6 
years) 
Rotterdam Study. Wolters 
et al 2016 
Population based study recruited from an area of Rotterdam. 
 
 This sample included those who attended centre baseline visit, were 
without dementia or stroke and where exam data was available for 
the assessment of OH. Baseline n=7983, 6626 were eligible or whom 
6303 had appropriate OH data.  
 
68.5 (8.6)  
 
All aged >=55 at baseline.  
59.70% 
Median 15.3 years 
(InterQuartile Range (IQR)  
 
8.3:20.8). OH assessed in 
1089-93, follow up until 2014.  
Singapore Longitudinal 
Aging Studies Cohort Yap 
et al 2008 
Community living population of Chinese adults.  
 
Study included 2321 free of stroke or cardiovascular disease at 
baseline. 1485 attended the follow up visit (24 died, 785 were lost to 
follow up, 441 refused, 339 could not be contacted). 
 
65.5 (7.4)  
 
All aged >=55 years at 
baseline. 
65.8% (in 
the full 
sample) 
One/two year follow up.  
 
Baseline was 2004/5 and 
follow up 2005/6 
Atherosclerosis Risk in 
Communities (ARIC) 
Study, Rose et al  2009 
12,702 middle-aged African American  and White men and women 
living in 4 communities: Maryland, Mississippi, Minnesota and 
North Carolina.  
 
At follow-up, 10,572, after exclusion of 1461 (no visit 4, death etc), 
337 (no cognition test), and 332 (incident stroke). 
No OH 53.9 (53.8-54.0),  
 
with OH (57.3 (56.8-57.7) 
No OH 
54.9  
 
with OH 
55.8  
Baseline (1987-89) plus 3 
triennial visits  
(last one 1996-99). 
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Malmö Preventive Project. 
Holm et al 2017. 
33,346 individuals living in Malmö.  
At follow up 18,204 were available. Missing data stated to range 
from 3 to 365 cases for different variables and these cases were not 
included in the respective analyses.  
 
45 (7) 
 
37% 
time from baseline to follow-
up visit 23 years (4),  
mean time from baseline to 
follow up for incident 
dementia 28 (4) years.  
Baseline 1974-1992, follow up 
2002-2006. Mean 
Progetto Veneto Anziani 
Study. Curreri et al 2016 
3099 community dwelling participants enrolled.  
1408 with data at follow up and without cognitive impairment 
(defined as an MMSE score <=24) 
71.4 (5.2)  
range 65-96 
59.40% 
Mean follow-up 4.4 years. 
Baseline 1995-1997. 
Three-City Study. Cremer 
et al 2017 
7425 recruited from the electoral roll in three French cities. 
Excluding those without prevalent dementia and with BP measures  
73.4 (4.9)  
all aged 65 or over at 
baseline  
60.50% 
Mean follow up 7.5 years 
Baseline 1999-2001, visits 
every 2/3 years. 
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Supplemental table 2   Results from longitudinal studies reporting on orthostatic hypotension and cognitive outcomes in those without prior cognitive impairment.  
Study  Assessment of OH Cognitive outcomes  Analysis methods  Result  
Swedish Good 
Aging in 
Skåne Study. 
Elmståhl et al 
2014 
Orthostatic hypotension was defined as a 
fall of >20mmHg SYSTOLIC BP or 
>10mmHg DIASTOLIC BP from supine 
pressure, after standing for 1-10 minutes 
or a fall of >40mmHg SYSTOLIC BP or 
>20 mmHg DIASTOLIC BP 
immediately after standing.  
 
Comprehensive examination by a 
physician including questions about 
symptoms such as unsteadiness, 
blackouts 
 
SGASS study also classified Orthostatic 
Intolerance (OI) as those with a BP (BP) 
fall less than that required for OH but 
with the presence of relevant symptoms 
e.g. unsteadiness (22). 
BP measured by a mercury 
sphygmomanometer. 
Dementia  
 
 
Incident dementia diagnosed in 
accordance with the Diagnostic 
Statistical Manual (DSM)IV.  
 
Objective memory loss was 
defined as a follow up score of 0 
or 1 on the 3 word recall sub-
score of the MMSE in the absence 
of subjective memory loss.  
 
Subjective memory loss was also 
collected. MCI was defined as 
either subjective or objective 
memory loss at follow up.  
 
 
Logistic regression 
comparing those 
who developed 
each outcome 
against those that 
developed none of 
the outcomes 
19% had OH,  
28% had past or present OI.  
64% had hypertension 
Adjusted for age 
 
 
Controls vs objective memory loss  
OH OR 0.95 (0.68:1.33) 
OI OR 1.10 (0.83:1.47) 
Controls vs subjective memory loss 
OH OR 1.07 (0.68:1.69) 
OI OR 1.55 (1.06:2.27) 
Controls vs MCI 
OH OR1.23 (0.75:2.00) 
OI OR2.01 (1.33:3.05) 
Controls vs dementia 
OH OR1.93 (1.19:3.14) 
OI OR0.90 (0.55:1.50) 
Rotterdam 
Study. Wolters 
et al 2016 
OH was based on change from supine to 
standing at 1, 2 and 3 minutes after 
standing and a fall of >=20mmHg 
SYSTOLIC BP or >=10mmHg 
DIASTOLIC BP within 3 minutes. Also 
categorised OH as >=20/10 but <30/15, 
>=30/15 but <40/20 and >=40/20   
 
BP was recorded by an automated 
machine, a Dinamap Critikan. 
Dementia 
 
 
Screening at baseline and follow 
up used the Mini-Mental State 
Exam (MMSE) and Geriatric 
Mental State Schedule (GMS). 
 
An MMSE <26 or a GMS >0 
triggered a more comprehensive 
exam with CAMDEX.  
 
Record linkage was also used to 
identify case of dementia.  
 
Proportional 
hazards regression 
to examine the 
relationship 
between OH and 
later dementia or 
death. 
18.6% with OH,  
30.6% in those >=75 years 
 
Adjusted for age, sex, SYSTOLIC BP, DIASTOLIC 
BP, antihypertensive use, diabetes, ratio of total 
cholesterol to High Density Lipoprotein (HDL) 
cholesterol, lipid lowering medication, smoking 
status, alcohol intake, anticholinergic medication, 
Body Mass Index (BMI) and apoe genotype.  
 
 
For dementia HR 1.15 (1.00:1.34) 
For Alzheimers disease  HR 1.17 (0.99:1.37) 
For vascular dementia HR 1.20 (0.73:1.96) 
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Diagnosis of dementia was made 
using the DSMIIIR and the 
NINCDS ADRDA for 
Alzheimer's Disease and NINDS 
AIREN for Vascular dementia.  
Also state that antihypertensive treatment had no 
effect. 
Singapore 
Longitudinal 
Aging Studies 
Cohort Yap et 
al 2008 
OH was defined as a fall in SYSTOLIC 
BP of >=20mmHg  or a fall of 
>=10mmHg in DIASTOLIC BP after 3 
minutes standing from supine. 
 
BP measured by a mercury 
sphygmomanometer. 
Cognitive change  
 
 
Assessment was using the 
MMSE. An MMSE <24 was 
categorised as cognitive 
impairment, a fall of >=1 point 
was categorised as cognitive 
decline.  
 
An additional analysis was carried 
out using >= 2 point fall to 
indicated cognitive decline. 
Logistic regression 
was used to 
examine the 
relationship 
between baseline 
OH and cognitive 
decline. 
16.6% had OH.  
 
Adjusted for age, sex, education, vascular risk factors 
(dyslipidaemia, diabetes, smoking) anaemia, apoeE4, 
BMI, depression, BP level, use of BP altering 
medication, duration of self reported hypertension, 
baseline MMSE and length of follow up. 
 
 
For the whole sample the results for cognitive decline 
were OR0.87 (0.61:1.23) 
 
For those with hypertension OR0.84 (0.51:1.38) 
Atherosclerosi
s Risk in 
Communities 
(ARIC) Study, 
Rose et al  
2009 
Orthostatic fall calculated as difference 
between average standing and supine BP 
following 20 minutes supine rest, BP 
taken every 2 seconds for 2 minutes, 
followed by repeat procedure with 
subject standing. OH was defined as 
decrease in systolic BP (BP) by >= 20 
mm Hg or diastolic BP by >=10 mm Hg 
upon standing.  
BP measured with Dinamap 18465X 
oscillometric device 
Cognitive change 
  
 
At visit 2 and 4, subjects 
completed a Delayed Word Recall 
Test (DWRT), a Digit Symbol 
Substitution Test (DSST) (subtest 
of Wechsler Adult Intelligence 
Scale -Revised, and The 
Controlled Oral Word 
Association Test (Word Fluency 
Test WFT) of the Multilingual 
Asphasic Examination. 
Quintiles of change 
in cognitive 
performance 
between visit 2 and 
4 calculated.  
 
Logistic regression 
analysis with lowest 
quintile compared 
with rest) to 
estimate association 
between OH and 
change in cognition, 
adjusted for various 
covariates. 
5.1% with OH.             
 
Association between baseline OH and cognitive 
decline over approx. 6 years (visit 2 to 4)              
 
Delayed word recall OR1.15 (0.94:1.42)   
Digit symbol substitution 1.13 (0.90:1.4);  
Word fluency 1.03 (0.82:1.28),  
 
each adjusted for age, race/centre, gender, education, 
Systolic BP, antihypertensive medication.  
 
 
Delayed word recall 1.08(0.86:1.35);  
Digit symbol substitution 1.05(0.83: 1.35); 
Word Fluency 1.03(0.80:1.31)  
 
each adjusted for covariates listed above plus current 
smoking and drinking, diabetes, carotid intima media 
thickness, low ankle brachial index, low density 
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lipoprotein cholesterol, resting heart rate, prevalent 
CHD, cancer, fair/poor self-reported health 
Malmö 
Preventive 
Project. Holm 
et al 2017. 
OH defined as a fall of >=20mmHg 
systolic BP and or a fall of >=10mmHg 
diastolic BP  after supine rest for 10 
minutes and standing for one minute. 
Article specifies that all BP values were 
rounded up to nearest 5 mmHg and the 
man value of two measures taken at each 
position was used.  
 
BP measured by a mercury 
sphygmomanometer. 
Dementia  
 
 
Dementia diagnosis taken from 
the Swedish National Patient 
Register (SNPR)  from baseline 
until Dec 2009.  
 
Dementia diagnoses were 
validated through review of 
medical records with physician 
input. 
Cox regression  
2.1% had OH. 
 
OH HR 1.18 (0.73:1.89) 
 
Per 10mmHg fall; 
Systolic BP fall HR 1.02 (0.89:1.15) 
Diastolic BP fall HR 1.22 (1.01:1.44) 
Adjusted for age, gender, antihypertensive treatment, 
smoking, diabetes, prevalent cardiovascular disease, 
plasma cholesterol.  
Progetto 
Veneto 
Anziani Study. 
Curreri et al 
2016 
OH defined as a fall of >=20mmHg 
systolic BP and or a fall of >=10mmHg 
diastolic BP in BP measures taken after 1 
or 3 minutes of standing and after supine 
rest for 5 minutes.  
BP measured by a mecury 
sphygnomnometer. 
Cognitive change  
 
Mini Mental State Exam (MMSE) 
 
A drop in MMSE of >=3 points 
classified as cognitive decline and 
a score of <=24 as cognitive 
impairment 
States that Odds 
ratios were used.  
18.3% with OH.  
Cognitive decline OR0.78 (0.69:1.05) 
adjusted for age and formal education using 
coefficients recommended for the Italian population 
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Three-City 
Study. Cremer 
et al 2017 
OH defined as a fall of >=20mmHg 
systolic BP and or a fall of >=10mmHg 
diastolic BP in BP measures taken 
immediately after standing and after 
supine rest for 5 minutes. Analyses also 
carried out with mild OH defined as  a 
fall of >=10mmHg systolic BP and or a 
fall of >=5mmHg diastolic BP and 
severe OH defined as  a fall of 
>=30mmHg systolic BP and or a fall of 
>=15mmHg diastolic BP 
BP measured by an automatic 
oscillometric device (OMRON CP750). 
Diagnosis of dementia using a 
three step procedure.  
Trained psychologists assessed 
cognitive function, at risk 
participants were seen by a 
neurologist at the Dijon site and 
all participants saw a neurologist 
at the Bordeaux and Montpelier 
sites. Final diagnosis made by an 
independent panel of experts 
based on DSMIV 
Cox proportional 
Hazard Regression 
models with 
delayed entry. Date 
of dementia was 
defined as midpoint 
between the visit 
without a diagnosis 
and the date the 
diagnosis was 
made. Also used an 
illness death 
semiparametric 
multistate model 
designed to take 
into account the 
competitive risk of 
death.   
13% with OH.  
For OH and dementia 
Cox model HR1.19 (0.98:1.46) 
Illness Death model HR 1.26 (1.03:1.53) 
For mild OH and dementia 
Cox model HR1.20 (1.04:1.40) 
Illness death model 1.23 (1.06:1.43) 
For severe OH and dementia 
Cox model HR1.54 (1.15:2.08) 
Illness death model HR1.51 (1.11:2.04)  
For OH and Alzheimer’s Disease 
Cox model HR1.19 (0.91:1.57) 
For OH and vascular dementia 
Cox model HR1.42 (0.92:2.15) 
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Supplemental table 3   Study quality  
Study  Recruitment bias? 
Exposure bias 
(assessments of risk factor 
exposure) 
Outcome bias (assessment tool, 
blinded assessors?) 
Follow up bias (attrition, 
length?) 
Overview, risk of bias 
Swedish Good Aging 
in Skåne Study. 
Elmståhl et al 2014 
Moderate Longitudinal 
population study but 
selected population.  
Low. Standard assessment 
of BP and OH 
Low. Standard assessment of 
cognitive function administered by 
trained assessors  
High. High attrition after 
baseline, some reasons given for 
attrition but no analyses to 
account for it.  
Moderate  
Rotterdam Study. 
Wolters et al 2016 
Moderate Longitudinal 
population study but 
selected population.  
Low. Standard assessment 
of BP and OH. Used the 
American Autonomic 
Society and American 
Academy of Neurology 
Consensus Committee 
definition of OH.  
Moderate. Standard assessment of 
cognitive function using a 
multistage process. Medical record 
based diagnosis are likely to be 
more open to bias than face to face 
assessment.   
Low. State that assessment was 
94% complete by the end of data 
collection. Imputed missing data 
in covariate and state that 
rerunning the analyses omitting 
the first 5 years or follow up to 
try to exclude reverse causality 
did not materially change the 
results.  
Low-Moderate  
Singapore 
Longitudinal Aging 
Studies Cohort Yap et 
al 2008 
Moderate. Selected 
population  
Low. Standard 
measurement of BP and 
definition of OH 
Moderate. Standard assessment for 
cognitive function but limited to a 
screening instrument. Fall of 1 
point to indicate impairment was 
not well justified.  
High. High attrition after 
baseline, some reasons given for 
attrition but no analyses to 
account for it. Missing data was 
excluded.  
Moderate  
Atherosclerosis Risk 
in Communities 
(ARIC) Study, Rose 
et al  2009 
Moderate. Participants 
sampled from 4 areas, 
but ethnic density 
varied between the 4 
communities, so 
possible bias in overall 
sample 
Low. Standard 
measurement of BP and 
definition of OH 
Low. Standard tests for assessment 
of cognitive function 
High. 17% lost for follow-up, 
some reasons given, mainly non-
attendance at 4th visit. 
Moderate 
Malmö Preventive 
Project. Holm et al 
2017. 
Moderate. Not clear 
whether population was 
representative. 
Moderate. Standard 
criteria for OH but not 
clear whether rounding of 
BP values took place 
before or after calculation 
of OH.  
High. Standard criteria used by 
research team to validate dementia 
diagnoses, however, diagnoses 
taken from medical registries may 
underestimate incidence and may 
be more subject to changing 
diagnostic patterns over time than 
High.. No details of reasons for 
attrition or adjustment. States 
that prevalence of OH lower, 
2.1% in those with follow up 
compared to 6.1% in the full 
baseline sample.  
Moderate-high 
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use of standard research protocols 
with direct participant assessment.  
Progetto Veneto 
Anziani Study. 
Curreri et al 2016 
Moderate, population 
was sampled to ensure 
male to female ratio of 
2:3 and older adults 
were over sampled.  
Low. Standard criteria for 
OH. 
Moderate . Standard assessment for 
cognitive function but limited to a 
screening instrument 
Moderate, however, details are 
provided regarding attrition or 
exclusion from analytical 
sample.  
Moderate  
Three-City Study. 
Cremer et al 2017 
Moderate, although 
sampled from the 
electoral role.  
Low. Standard criteria for 
OH. 
Low, standard criteria for diagnosis 
and regular visits.  
Moderate, however, details are 
provided regarding exclusion 
from analytical sample. Those in 
the study sample were younger 
and have fewer cardiovascular 
risk factors than those excluded.  
Low-Moderate  
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Supplemental table 4 Characteristics of those with Subclinical orthostatic fall with recent symptoms and Orthostatic 
Hypotension in the subset with symptom data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a global p-values from one-way analysis of variance; 
b There were no significant pairwise differences between the groups (Tukey-Kramer test, 5% level) 
c There was a significant pairwise difference between the “Neither” and “Orthostatic hypotension” groups (Tukey-
Kramer test, 5% level) 
d There was a significant pairwise difference between the “Neither” and “Orthostatic hypotension” groups and between 
the “Orthostatic Subclinical orthostatic fall with recent symptoms” and “Orthostatic hypotension” groups  (Tukey-
Kramer test, 5% level) 
e global p-value from W test (similar to F-test for one-way analysis of variance but more robust when there are unequal 
variances).   
f All the pairwise comparisons between the groups were significant (Tukey-Kramer test, 5%) 
g Examination of the adjusted Chi-squared residuals suggests there are no unusually high or low counts in any of the 
cells.   
h Examination of the adjusted Chi-squared residuals suggests a difference is between the “Neither” and “Orthostatic 
Subclinical orthostatic fall with recent symptoms”/“Orthostatic hypotension” groups. 
Population characteristics  
mean (Standard Deviation) or  
n (%) 
Neither  
 
 
N=1623 
Orthostatic 
Subclinical 
orthostatic fall 
with recent 
symptoms  
 
N=105 
Orthostatic 
hypotension 
 
N=381 
P-valuesa 
Age 83.45 (3.12) 83.13 (2.72) 83.83 (3.26) 0.05b 
Female 60.4 (980) 74.3 (78) 63.8 (243) 0.01g 
Sitting systolic BP – baseline 173.4 (9.8) 174.7 (10.0) 175.2 (10.0) <0.01c 
Sitting diastolic BP- baseline 89.7 (9.6) 91.9 (9.3) 90.5 (8.9) 0.07b 
Standing systolic BP- baseline 169.7 (11.1) 168.4 (11.3) 161.5 (11.4) <0.0001d 
Standing diastolic BP- baseline 89.3 (9.5) 89.6 (9.3) 82.2 (9.3) <0.0001d 
Systolic orthostatic fall- baseline 3.7 (6.2) 6.3 (5.3) 13.7 (8.0) <0.0001e,f 
Diastolic orthostatic fall- baseline 0.5 (4.8) 2.3 (4.6) 8.3 (5.2) <0.0001f 
Mini Mental State Exam (MMSE) 
score baseline 
25.2 (3.9) 25.1 (3.4) 24.5 (3.8) <0.01c 
Incident dementia  132 (8.1) 13 (12.4) 35 (9.2) 0.28 
Incident cognitive decline (Protocol 
definition: MMSE fall) 
462 (28.5) 40 (38.1) 139 (36.5) <0.01h 
Incident cardiovascular event (stroke, 
myocardial infarction, heart failure) 
97 (6.0) 13 (12.4) 26 (6.8) 0.03g 
Death 596 (5.9) 18 (17.1) 22 (5.8) P<0.0001i 
Follow up (baseline to last available 
data) 
2.4 (1.5) 2.3 (1.3) 2.1 (1.5) P<0.001 
Participants reporting light-headedness 
and or unsteadiness and or faintness as 
having bothered them ‘a lot’ or 
‘extremely’ during the preceding 
week. 
7 (0.43) 105 (100) 4 (1.1) N/A 
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i Examination of the adjusted Chi-squared residuals suggests a difference is between the “Neither” and  “Orthostatic 
hypotension”  groups and the “Orthostatic Subclinical orthostatic fall with recent symptoms” group. 
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Supplemental table 5 Results of proportional hazard regression analyses for systolic and diastolic OH separately. 
Stratified by age (80-84, >=85 years), sex and education. Adjusted for baseline sitting systolic and diastolic BP, trial 
treatment and presence of diabetes.  
 Cognitive decline Dementia Cognitive decline and 
cardiovascular events 
Dementia and 
cardiovascular 
events 
Hazard Ratio (95% 
Confidence Intervals 
(CI) 
HR (95% CI) HR (95% CI) HR (95% CI) 
Systolic OH  1.17 (0.91:1.50) 0.86 (0.50:1.49) 1.22 (0.97:1.54) 1.11 (0.75:1.62) 
Diastolic 
OH 
1.47 (1.23:1.75) 1.69 (1.22:2.34) 1.49 (1.26:1.75) 1.54 (1.18:2.00) 
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Supplemental table 6 Results of proportional regression analyses using a more severe definition Orthostatic Hypotension*.  
Stratified by age (80-84, >=85 years), sex and education. Adjusted for baseline sitting systolic and diastolic BP, trial treatment and presence of diabetes.  
 Cognitive decline Dementia Cognitive decline and 
cardiovascular events  
Dementia and cardiovascular 
events  
Number of 
events  
Hazard Ratio 
(95% 
Confidence 
Intervals (CI) 
Number of 
events 
HR (95% 
CI) 
Number of 
events 
HR (95% 
CI) 
Number of 
events 
HR (95% 
CI) 
Orthostatic 
Hypotension 
(OH) 
906 1.49 
(1.16:1.90) 
241 1.40 
(0.90:2.27) 
1021 1.51 
(1.19:1.90) 
498 1.35 
(0.92:1.98) 
 
*Defined as a fall of >20mmHg systolic BP ad or a fall of >10mmHg diastolic BP.  
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Supplementary analyses 1  
Summary meta-analysis 
 
Study * Ratio SE Approximate 95% CI  
1 1.93 0.247522 1.19 3.14 SGASS 
2 1.34 0.160709 0.98 1.84 HYVET 
3 1.19 0.101696 0.98 1.46 3 Cities 
4 1.18 0.24268 0.73 1.89 Malmö 
5 1.15 0.074662 1 1.34 Rotterdam 
 
Stratum Standardized Effect Standard Error % Weights (fixed, random)  
1 1.93 0.247522 4.688799 5.652385 SGASS 
2 1.34 0.160709 11.122669 12.8318 HYVET 
3 1.19 0.101696 27.777073 28.835204 3 Cities 
4 1.18 0.24268 4.877786 5.872458 Malmö 
5 1.15 0.074662 51.533673 46.808153 Rotterdam 
 
Fixed effects (inverse variance) 
Pooled * ratio = 1.211428 (95% CI = 1.090624 to 1.345612) 
Z (test test * Ratio differs from 1) = 3.578511  P = 0.0003 
Non-combinability of studies 
Cochran Q = 4.462408  (df = 4) P = 0.347 
Moment-based estimate of between studies variance = 0.002075 
I2 (inconsistency) = 10.4% (95% CI = 0% to 67.7%)  
Random effects (DerSimonian-Laird) 
Pooled * ratio = 1.221427 (95% CI = 1.086264 to 1.373409) 
Z (test * Ratio) = 3.342813  P = 0.0008 
Bias indicators 
Begg-Mazumdar: Kendall's tau = 0.8  P = 0.0833 (low power) 
Egger: bias = 1.632025 (95% CI = -1.031496 to 4.295546)  P = 0.1463 
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Appendix 1  
Abbreviations  
Blood Pressure BP 
Diagnostic Statistical Manual DSM 
Hazard Ratio HR 
Hypertension in the Very Elderly Trial HYVET 
Mini-Mental State Exam MMSE 
Orthostatic Hypotension  OH 
Subclinical Orthostatic Hypotension  SOH 
 
 
 
